Engineering Endomorphin-2 Analogs: Structural Modifications and Therapeutic Activity.

Endomorphin-2 (EM-2), an endogenous tetrapeptide (Tyr-Pro-Phe-Phe-NH2) with high affinity and selectivity for the μ-opioid receptor, plays a significant role in pain modulation and diverse physiological processes. This review systematically outlines recent advances in the synthesis, structural modification, and structure-activity relationships of EM-2. A broad spectrum of modification strategies is examined, including C- and N-terminal modifications, backbone and side-chain engineering, cyclization design, multi-site alterations, and the incorporation of specialized structural motifs. The influence of these modifications on receptor affinity, metabolic stability, analgesic efficacy, and side-effect profiles is critically evaluated. Key findings indicate that specific structural modifications, such as C-terminal hydrazidation and N-terminal dimethyltyrosine substitution, enhance receptor selectivity, reduce tolerance, and improve metabolic stability. Additionally, cyclization strategies further increase resistance to enzymatic degradation and enhance centrally mediated analgesic activity. The review concludes by identifying future research directions, underscoring the importance of multi-site modifications, advanced delivery systems, and thorough preclinical evaluation to advance the development of EM-2-based therapeutics.